BMS gets US FDA approval for Breyanzi to treat large B-cell lymphoma
The FDA approval was based on data from the Phase 3 TRANSFORM trial and Phase 2 PILOT study,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Jun 22
The FDA approval was based on data from the Phase 3 TRANSFORM trial and Phase 2 PILOT study,…
27 Jun 22
The investment will be implemented in two stages where the first stage will focus on developing vaccines, plasma,…
24 Jun 22
The expansion, which doubles the production of the highly potent active pharmaceutical ingredients (HPAPIs), builds on Merck’s 30…
24 Jun 22
The vaccine has also been recommended by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human…
23 Jun 22
The drug combination was indicated for metastatic solid tumours with BRAF V600E mutations in adults and children aged…
23 Jun 22
The FDA approval was based on data from seven randomised, double-blind clinical studies that evaluated Vaxneuvance in infants,…
22 Jun 22
A modified panel of CAFC reversed the decision upholding the validity of the Gilenya dosing regimen patent granted…
22 Jun 22
The study conducted at Heidelberg University Hospital, Germany showed that the company’s fasting-mimicking diet (FMD) improved microalbuminuria, markers…
21 Jun 22
The NMPA approval is based on the interim analysis of the Phase 3 ORIENT-15 clinical trial, in which…
21 Jun 22
Pfizer and Valneva have updated the terms of their existing collaboration and license agreement for the development of…